Clinical data | |
---|---|
AHFS/Drugs.com | Monograph |
MedlinePlus | a699060 |
License data | |
Pregnancy category |
|
Routes of administration |
Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 52% |
Metabolism | mostly non-enzymatic, partly hepatic (CYP2C19) |
Biological half-life | 1 - 1.5 hours |
Excretion | 90% renal |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
PDB ligand | |
ECHA InfoCard | 100.123.408 |
Chemical and physical data | |
Formula | C18H21N3O3S |
Molar mass | 359.444 g/mol |
3D model (Jmol) | |
Chirality | Racemic mixture |
|
|
|
|
Rabeprazole /ˌræ.ˈbɛp.ræ.zɔːl/ is an antiulcer drug in the class of proton pump inhibitors. It was developed by Eisai Co. and is available worldwide under many brand names.
Short-term treatment in healing and symptomatic relief of duodenal ulcers and erosive or gastroesophageal reflux disease (GERD); maintaining healing and reducing relapse rates of heartburn symptoms in patients with GERD; treatment of daytime and nighttime heartburn and other symptoms associated with GERD; long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome and in combination with amoxicillin and clarithromycin to eradicate Helicobacter pylori.
Rabeprazole adverse reactions/side effects include:
Rabeprazole decreases the concentration of in the plasma (in 33%), increases the concentration of digoxin (in 22%), and does not interact with liquid antacids. Rabeprazole is compatible with any medicine metabolized by the CYP450 (theophylline, warfarin, diazepam, phenytoin).